Publications

5808 Results

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

Authors
M Othus;S Patel;Y Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock
Journal / Conference
Journal of the National Cancer Institute Apr 1;117(4):692-700
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39565908
PMC
PMC11972677
Study Number(s)
S1609

TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized Phase III Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response

Authors
M Ong;A Sokolova;S Hotte;T Dorff;K Chi;A Wyatt;A Goldkorn;M Kolinsky;M Brundage;A Ndika;S Lerner;W Parulekar;K Ding;M Jafri
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), tip; Abstract # TPS5129 Poster Bd # 318b
Year
2025
Research Committee(s)
Genitourinary
Study Number(s)
CCTG-PR26

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Authors
T Parker;A Rosenthal;V Sanchorawala;H Landau;E Campagnaro;P Kapoor;N Neparidze;S Girnius;P Hagen;E Scott;A Hoering;B Durie;R Orlowski
Journal / Conference
Blood Sep 9:blood.2024027962
Year
2025
Research Committee(s)
Myeloma
PMID
PMID40925099
Study Number(s)
S1702

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

Authors
P Torka;A Bock;E Nazarenko;Y Xu;J Vaughn;S Thiruvengadam;A Major;K Sekaran;D Reef;C Lee;G Smilnak;E Luttwak;V Patel;H Shah;A Ip;G Baek;R Mynam;D Sano;D Gerber;A Falade;M Palmeri;R Mrad;M Iqbal;J Sharp;T Voorbees;P Geethakumari;J Rbodes;U Durani;H Cherng;Y Karimi;P Pophali;M Di;T Feldman;J Svoboda;K Shanmugasundaram;A Niu;N Grover;R Karmali;A Herrera;C Diefenbach;N Epperla
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #3622 poster. Blood (2025) 146 (Supplement 1): 3622
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

Authors
C Casulo;H Li;A Herrera;S Castellino;S Rutherford;K Davison;A Punnett;B Kahl;J Leonard;S Smith;J Song;K Kelly;J Friedberg;M LeBlanc;S Parsons;A Rodday;A Evens
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL), #154 oral. Blood (2025) 146 (Supplement 1): 154
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Authors
S Jiwani;M Fang;C Yeung;X QU;X Chen;B Wood;A Zak
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #340, oral. Blood (2025) 146 (Supplement 1): 340. 10.1182/blood-2025-340.
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH

Emerging strategies for drug-based cancer risk reduction

Authors
Daca-Alvarez M
Journal / Conference
Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473708
Year
2025
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Inclusive Cancer Clinical Trial Participation – A Recipe for New Treatment Advances

Authors
Unger JM
Journal / Conference
JAMA Netw Open. 2025 Jun 2;8(6):e2515210
Year
2025
Research Committee(s)
Cancer Care Delivery

Financial toxicity: A ubiquitous condition in patients with cancer

Authors
Unger JM
Journal / Conference
Cancer. 2025 Feb 15;131(4):e35748
Year
2025
Research Committee(s)
Cancer Care Delivery

Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups

Authors
TJ Hoffman
Journal / Conference
Nat Genet, 2025 Feb;57(2), 334-344
Year
2025
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
Study Number(s)
S0000, SWOG-9217